Those three KDs are interrelated with other diabetes genes and are involved in the downstream pathways such as the interleukin-6/signal transducer and the activator of the transcription 3 (STAT3) and immune/inflammation responses [65,66,67,68,69,70,71]; thus, they have implications as novel targets for IGF/IR-associated disorders, including T2DM. This evidence concerns the gene STAT3 and diabetes mellitus.